Interpace Biosciences Inc.

Company Overview

Interpace Biosciences Inc., formerly known as Interpace Diagnostics Group Inc. is developing and commercializing molecular diagnostic tests for thyroid, pancreatic and other cancers. The main tests marketed include ThyGenX Thyroid Oncogene Panel, ThyraMIR Thyroid miRNA Classifier, PancraGen and RespriDx.

PancraGen is a pancreatic cyst molecular test than can help in pancreatic cyst diagnosis and pancreatic cancer risk assessment and which uses the PathFinder platform.

The ThyGenX test uses NGS to analyze more than 100 genetic alterations related to papillary and follicular carcinoma, the most common forms of thyroid cancers. This test assesses thyroid nodules for risk of malignancy.

In order to increase the specificity of the ThyGenX test, Interpace offers this test in combination with its ThyraMIR miRNA expression classifier test. ThyraMIR analyzes the expression levels of 10 miRNAs related to cancer. ThyraMIR assesses thyroid nodules risk of malignancy using a gene expression RT-qPCR platform.

These tests help physicians differentiate benign and malignant genotypes in indeterminate thyroid nodules. The tests are offered on the LabCorp test menu as part of an alliance between the two companies.

In the liquid biopsy space, Interpace has an alliance with Viatar CTC Solutions to use the PancraGen assay together with Viatar’s CTC cell collection technology. The objective is an assay that can be used to help assess indeterminate pancreatic cancer biopsies in patients who have pancreatic cysts. Success in this program will enable a liquid biopsy assay for early detection of pancreatic cancer.

In July 2019, Interpace acquired the Biopharma Services business of Cancer Genetics. This acquisition strengthened the oncology testing and services business for Interpace by adding new clients and growth revenues.

Financial Highlights (FY 2024)

Company's Business Segments

• Molecular Diagnostic Clinical Services : The company offers esoteric molecular diagnostic testing and pathology services to aid physicians evaluate cancer risk in patients with indeterminate biopsies and perceived high risk of cancer from clinical features.